SuviCa Awarded a Phase II SBIR contract to develop a new screen

SuviCa is pleased to announce that it received a 1.9M$ Phase II SBIR contract from the National Cancer Institute to develop a high throughput assay with a clonogenic endpoint that will be used to screen for novel radiation modulators of cancer.